Apixaban to Enoxaparin Transition Timing
Apixaban should be discontinued and therapeutic parenteral anticoagulation should be started at the time the next scheduled apixaban dose would have been due. [1] Overlap with enoxaparin is not generally required for this transition. [1]
Medication Selection Algorithm
- Direct oral factor Xa inhibitor (apixaban) should be stopped when the next dose is due. [1]
- Low–molecular-weight heparin (enoxaparin) should be initiated as the first enoxaparin dose at that same time point. [1]
Initiation Thresholds and Indications
- The transition should follow the patient’s intended enoxaparin regimen (treatment-dose versus prophylaxis-dose) rather than the apixaban dose history. [1]
- Renal impairment should be considered when selecting and dosing enoxaparin because enoxaparin exposure increases with reduced kidney function. [1]
Monotherapy Versus Combination Therapy
- Apixaban plus enoxaparin coadministration is not generally required during conversion when both agents are being used as the sole anticoagulant across the transition. [1]
Timing Details for the First Enoxaparin Dose
- For apixaban → enoxaparin: discontinue apixaban and begin enoxaparin at the usual time of the next dose of apixaban. [1]
- This “start at next scheduled dose” approach is consistent across practical DOAC transition guidance. [2]
Common Pitfalls to Avoid
- Starting enoxaparin before the next scheduled apixaban dose can lead to unintended anticoagulant overlap. [1]
- Delaying enoxaparin beyond the time the next apixaban dose would be due can create a period of sub-therapeutic anticoagulation. [1]
Periprocedural Bridging Exceptions
- Bridging anticoagulation immediately after stopping apixaban for 24–48 hours before an intervention is not generally required in labeling guidance for peri-procedural management. [3]
- Peri-procedural timing should be handled with a procedure-specific protocol rather than the routine apixaban-to-enoxaparin conversion rule. [3]